Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer
- PMID: 34767761
- DOI: 10.1016/j.ccell.2021.11.001
Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer
Abstract
Immune checkpoint blockade plus chemotherapy is emerging as a standard treatment for some patients with triple-negative breast cancer (TNBC). In this issue of Cancer Cell, Zhang et al. employ extensive single-cell immune compartment analyses of pre- and post-therapy TNBC, and they reveal potential mechanisms of T cell activation and patterns of immune evolution that may inform future biomarkers of response and clinical benefit.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Comment on
-
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer.Cancer Cell. 2021 Dec 13;39(12):1578-1593.e8. doi: 10.1016/j.ccell.2021.09.010. Epub 2021 Oct 14. Cancer Cell. 2021. PMID: 34653365
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources